Wilson Sonsini Goodrich & Rosati advised Ambagon Therapeutics on the deal. Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced...
You must be a Standard 1 Year member to access this content.
Grandall advised Yangzhou Yuanbo on the offering. Yangzhou Yuanbo Investment and Development Co. executed its offering of USD 46 million senior unsecured fixed rate bond with...
You must be a Standard 1 Year member to access this content.
Grandall advised Yangzhou Yuanbo on the offering. Yangzhou Yuanbo Investment and Development Co. executed its offering of USD 46 million senior unsecured fixed rate bond with...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
You must be a Standard 1 Year member to access this content.
